<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379625</url>
  </required_header>
  <id_info>
    <org_study_id>FD003895</org_study_id>
    <nct_id>NCT01379625</nct_id>
  </id_info>
  <brief_title>Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder</brief_title>
  <acronym>Triheptanoin</acronym>
  <official_title>Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Humans eat long-chain fat in their diet and use it for energy during exercise and during
      periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use
      dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with
      exercise or illness. They can also develop a heart that does not function properly. These
      patients are tired and expend less energy than people who do not have a long-chain fatty acid
      oxidation disorder. However, they can use a supplement oil called medium chain triglyceride
      or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease
      the muscle pain and increase the heart function and the amount of energy in patients with
      long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment: Patients with a long-chain fatty acid oxidation disorder will be recruited
      through our clinic, past research participants, a patient support website, and recruitment
      letters mailed to physicians around the US. We will enroll 16 subjects at OHSU and 16
      subjects at the University of Pittsburgh, age 7 to 40, with a disorder in fatty acid
      oxidation.

      Procedures: Subjects will be admitted to the clinical research center for 4 days. They will
      collect all their urine for 24 hours. Heart function will be measured using ultrasound an
      electrocardiogram (ECG). The motion of the heart will be measured by magnetic resonance
      imaging (MRI). For this test, the patient lies in the magnetic field of the MRI machine in
      the Advanced Imaging Resource Center (AIRC) for about 45 minutes. The amount of muscle and
      fat in the whole body and inside the liver and muscle will be measured by MRS and by dual
      X-ray absorptiometry (DEXA). Subjects will walk on a treadmill for about 45 minutes. The
      amount of Calories they use, their heart rate, and if they burn fat or carbohydrates will be
      measured. Blood samples will be collected before and after exercise. A meal test will be used
      to determine how much fat they burn. The subjects will drink a liquid breakfast with a stable
      isotope labeled fat in the breakfast. Breath and blood samples will be collected before and
      after the meal. The amount Calories burned by each subject will be measured when they are at
      rest on a bed by indirect calorimetry. The amount of Calories burned by subjects when they
      are doing their routine daily activities will be measured at home by doubly labeled water.
      All of these tests will be done at baseline. Then, subjects will be randomly assigned to
      consume MCT (current standard of care) or triheptanoin at 20% of their estimated Calorie
      needs for 4 months. The subject and/or the parent will be taught how to use the supplement
      oil in their diet for cooking and baking. The subject will be sent home and the oil will be
      shipped to their home. The study coordinator will call the subject or subject's guardian each
      week to monitor the subject's diet, potential side effects and assist with diet planning. At
      the end of 4 months, all of the baseline tests will be repeated.

      Triheptanoin is experimental oil. It is a clear, odorless oil that can be mixed with foods
      and used in cooking. Almost all oils are made from even chains of carbon molecules.
      Triheptanoin is different because the carbon chains are odd in number. The co-investigator of
      this study at the University of Pittsburgh, Dr. Jerry Vockely, holds an IND for the
      prescription, and use of triheptanoin in humans (IND 106011).

      Data Analysis: The change in exercise ability, heart function, Calories used and body fat
      after 4 months will be compared between subjects randomized to MCT versus triheptanoin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy Expenditure</measure>
    <time_frame>change from baseline after 4 months of treatment</time_frame>
    <description>Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection Fraction</measure>
    <time_frame>4 months</time_frame>
    <description>Change in resting ejection fraction over 4 month treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Heart Rate</measure>
    <time_frame>change from baseline to 4 months of treatment</time_frame>
    <description>Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency</condition>
  <condition>Carnitine Palmitoyltransferase 2 (CPT2) Deficiency</condition>
  <condition>Mitochondrial Trifunctional Protein (TFP) Deficiency</condition>
  <condition>Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency</condition>
  <arm_group>
    <arm_group_label>Medium Chain Triglyceride (MCT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to consume 20% of energy from MCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triheptanoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject randomized to consume 20% of energy from triheptanoin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin</intervention_name>
    <description>Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
    <arm_group_label>Medium Chain Triglyceride (MCT)</arm_group_label>
    <arm_group_label>Triheptanoin</arm_group_label>
    <other_name>IND 113386</other_name>
    <other_name>C7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency,
             Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional
             Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD)
             deficiency

          -  &gt; 7 years

          -  Ability to travel to CRC to participate

          -  Ability to follow protocol

        Exclusion Criteria:

          -  Hgb &lt; 10 g/dl

          -  Peripheral neuropathy that limits ability to complete treadmill studies

          -  Inclusion in another research study that alters macronutrient intake

          -  Pregnant females

          -  history of myocardial infarction or cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie B Gillingham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Melanie B Gillingham</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>fatty acid oxidation</keyword>
  <keyword>triheptanoin</keyword>
  <keyword>long-chain fatty acid oxidation disorders</keyword>
  <keyword>LCHADD</keyword>
  <keyword>VLCADD</keyword>
  <keyword>CPT2</keyword>
  <keyword>TFP</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medium Chain Triglyceride (MCT)</title>
          <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
        <group group_id="P2">
          <title>Triheptanoin</title>
          <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were 7 years of age or greater with one of 3 fatty acid oxidation disorders: CPT2, VLCAD or LCHAD/TFP.</population>
      <group_list>
        <group group_id="B1">
          <title>Medium Chain Triglyceride (MCT)</title>
          <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
        <group group_id="B2">
          <title>Triheptanoin</title>
          <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="12.7"/>
                    <measurement group_id="B2" value="27.2" spread="15.9"/>
                    <measurement group_id="B3" value="24.8" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="26.8"/>
                    <measurement group_id="B2" value="62.1" spread="23.5"/>
                    <measurement group_id="B3" value="64.6" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejection Fraction</title>
          <description>Echocardiogram ejection fraction as a %. This was not completed for all the participant. There were 11 participants in the MCT group and 10 participants in the Triheptanoin group who are included in this baseline measure.</description>
          <population>There was a change in the protocol from cardiac MRI to echo after the 1st 7 participants and some of the echocardiogram results were unreadable due to technical errors. A total of 11 subjects in the MCT and 10 subjects in triheptanoin group were analyzed.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="5.3"/>
                    <measurement group_id="B2" value="57" spread="9.2"/>
                    <measurement group_id="B3" value="59.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Heart Rate</title>
          <description>All participants performed a moderate intensity exercise treadmill walking at an estimated 60% of their estimated max heart rate for 40 minutes. The exercise heart rate at minute 30 when the exercise was steady is reported.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132" spread="7"/>
                    <measurement group_id="B2" value="125" spread="12"/>
                    <measurement group_id="B3" value="128" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Energy Expenditure</title>
          <description>Total energy expenditure in kcal/day was measured by doubly labled water in 12 subjects in the MCT group and in 13 of the subjects in the Triheptanoin group.</description>
          <population>One participant in the MCT group and one participant in the Triheptanoin group did not return their urine samples for the doubly labeled water analysis. A total of 15 in each group were analyzed.</population>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2567" spread="604"/>
                    <measurement group_id="B2" value="2230" spread="512"/>
                    <measurement group_id="B3" value="2392" spread="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Energy Expenditure</title>
        <description>Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.</description>
        <time_frame>change from baseline after 4 months of treatment</time_frame>
        <population>One subject in each group did not complete the doubly labeled water measures. A total of 15 in each group measured total energy expenditure at baseline and at the end of the study. This value compares the change over treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Medium Chain Triglyceride (MCT)</title>
            <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
          <group group_id="O2">
            <title>Triheptanoin</title>
            <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
        </group_list>
        <measure>
          <title>Energy Expenditure</title>
          <description>Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.</description>
          <population>One subject in each group did not complete the doubly labeled water measures. A total of 15 in each group measured total energy expenditure at baseline and at the end of the study. This value compares the change over treatment.</population>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73" spread="335"/>
                    <measurement group_id="O2" value="107" spread="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ejection Fraction</title>
        <description>Change in resting ejection fraction over 4 month treatment period</description>
        <time_frame>4 months</time_frame>
        <population>Change in resting ejection fraction over 4 month treatment period calculated as: 4 month ejection fraction-baseline ejection fraction. Only participants with available data are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Medium Chain Triglyceride (MCT)</title>
            <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
          <group group_id="O2">
            <title>Triheptanoin</title>
            <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction</title>
          <description>Change in resting ejection fraction over 4 month treatment period</description>
          <population>Change in resting ejection fraction over 4 month treatment period calculated as: 4 month ejection fraction-baseline ejection fraction. Only participants with available data are included in this analysis.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="4.16"/>
                    <measurement group_id="O2" value="2.14" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Heart Rate</title>
        <description>Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.</description>
        <time_frame>change from baseline to 4 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medium Chain Triglyceride (MCT)</title>
            <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
          <group group_id="O2">
            <title>Triheptanoin</title>
            <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Heart Rate</title>
          <description>Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="9.6"/>
                    <measurement group_id="O2" value="-12.6" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medium Chain Triglyceride (MCT)</title>
          <description>Subjects randomized to consume 20% of energy from MCT
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
        <group group_id="E2">
          <title>Triheptanoin</title>
          <description>Subject randomized to consume 20% of energy from triheptanoin.
Triheptanoin: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>21 CRF 312</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Upset</sub_title>
                <description>Gastrointestinal Upset including stomach pain, burning, or cramping.</description>
                <counts group_id="E1" events="38" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" events="24" subjects_affected="11" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea/Loose stools</sub_title>
                <description>Report of diarrhea or loose stools during the treatment period.</description>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <description>Acute rhabdomyolysis requiring hospitalization is expected. This is a known complication of fatty acid oxidation disorders.</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>muscle pain/ elevated CPK</sub_title>
                <description>This is an anticipated adverse event because muscle pain with elevated CPK is a complication of a fatty acid oxidation disorder.</description>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Melanie Gillingham</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-1682</phone>
      <email>gillingm@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

